



CT2711 US - NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Loriann Kazmercyk
Type or print name

Signature

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
JEFFREY LEE ROMINE, ET AL.
APPLICATION NO: 10/637,099

ART UNIT: 1648
EXAMINER:

FILED: 08/08/2003

FOR: IMINOTHIAZOLIDINONES AS INHIBITORES OF HCV REPLICATION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding PCT International application. Copies of the references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Date: *Oct. 25, 2005*



Warren, K. Volles
Attorney for Applicant
Reg. No. 33,810
Phone: 203-677-6997

SIDS October 2005

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/637099
Filing Date	08/08/03
First Named Inventor	Jeffrey Lee Romine
Art Unit	1614
Examiner Name	
Attorney Docket Number	CT2711-US - NP

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	2AA	SARRAZIN, C. et al., "Mutations in the Protein Kinase-Binding Domain of the NS5A Protein in Patients Infected with Hepatitis C Virus Type 1a Are Associated with Treatment Response," The Journal of Infectious Diseases, Vol. 181, pp. 432-441 (2000)	
	2AB	FRANGEUL, L. et al., "Mutations in NS5A Region of Hepatitis C Virus Genome Correlate With Presence of NS5A Antibodies and Response to Interferon Therapy for Most Common European Hepatitis C Virus Genotypes," Hepatology, Vol. 28, No. 6, pp. 1674-1679 (1998)	
	2AC	WOITAS, R.P. et al., "Differential expansion of T-cell receptor variable beta subsets after antigenic stimulation in patients with different outcomes of hepatitis C infection," Immunology, Vol. 106, pp. 419-427 (2002)	
	2AD	WANG, Y.S. et al., "Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications," Advanced Drug Delivery Reviews, Vol 54, pp. 547-570 (2002)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant